PDEX vs NSYS vs LIQT vs ATRC vs MMSI

For growth investors, Pro-Dex, Inc.

(PDEX) is the stronger pick with 23. 7% revenue growth year-over-year, versus -8. 0% for Nortech Systems Incorporated (NSYS). Pro-Dex, Inc. (PDEX) offers the better valuation at 21. 5x trailing P/E (24. 1x forward), making it the more compelling value choice. Analysts rate Pro-Dex, Inc. (PDEX) a "Buy" — based on 1 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Pro-Dex, Inc.

(PDEX) is the cheapest at 21. 5x versus Merit Medical Systems, Inc. at 29. 3x. On forward P/E, Merit Medical Systems, Inc. is actually cheaper at 15. 5x — notably different from the trailing picture, reflecting expected earnings growth.

Over the past 5 years, Nortech Systems Incorporated (NSYS) delivered a total return of +103.

2%, compared to -96. 1% for LiqTech International, Inc. (LIQT). Over 10 years, the gap is even starker: PDEX returned +1423% versus LIQT's -90. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Pro-Dex, Inc.

(PDEX) is the lower-risk stock at 0. 33β versus AtriCure, Inc. 's 1. 03β — meaning ATRC is approximately 216% more volatile than PDEX relative to the S&P 500. On balance sheet safety, AtriCure, Inc. (ATRC) carries a lower debt/equity ratio of 18% versus 117% for LiqTech International, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Pro-Dex, Inc.

(PDEX) is pulling ahead at 23. 7% versus -8. 0% for Nortech Systems Incorporated (NSYS). On earnings-per-share growth, the picture is similar: Pro-Dex, Inc. grew EPS 345. 0% year-over-year, compared to -119. 7% for Nortech Systems Incorporated. Over a 3-year CAGR, ATRC leads at 17. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Pro-Dex, Inc.

(PDEX) is the more profitable company, earning 13. 5% net margin versus -51. 7% for LiqTech International, Inc. — meaning it keeps 13. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PDEX leads at 16. 1% versus -50. 3% for LIQT. At the gross margin level — before operating expenses — ATRC leads at 74. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Merit Medical Systems, Inc.

(MMSI) trades at 15. 5x forward P/E versus 370. 7x for AtriCure, Inc. — 355. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ATRC: 82. 3% to $50. 67.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Pro-Dex, Inc.

(PDEX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 33), +1423% 10Y return). Both have compounded well over 10 years (PDEX: +1423%, ATRC: +95. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (PDEX (Healthcare) and NSYS (Technology) and LIQT (Industrials) and ATRC (Healthcare) and MMSI (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: PDEX is a small-cap high-growth stock; NSYS is a small-cap quality compounder stock; LIQT is a small-cap quality compounder stock; ATRC is a small-cap quality compounder stock; MMSI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.